GlassScriptPhysician profile
Rene Romig
NPI 1528563020
$747.99
in general payments reported to CMS, 2019-2025
18 companies · $75.99 in 2025
The $75.99 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.83 · 2023: $364 · 2024: $256 · 2025: $75.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $121.27 | 2023-2024 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $93.10 | 2023-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.60 | 2023-2024 | Caplyta |
| Alkermes, INC. | $56.71 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Dexcom, INC. | $51.37 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $51.33 | 2024-2025 | Shingrix, Bexsero, Arexvy |
| Abbvie INC. | $50.69 | 2023-2024 | Vraylar |
| Corium, LLC | $43.96 | 2023 | Azstarys |
| Exact Sciences Corporation | $39.24 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $35.92 | 2024 | |
| Merck Sharp & Dohme LLC | $25.81 | 2022-2024 | Gardasil, Capvaxive, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $21.28 | 2025 | |
| Abbott Laboratories | $19.62 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $18.82 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.29 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $15.04 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $14.66 | 2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.28 | 2023 | Spiriva Respimat, Stiolto Respimat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Romig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.